YDES — YD Bio Limited Stock Price, Chart & AI Report

Positive Jul 2, 2026 • 12:00 UTC GlobeNewswire Inc. • Yd Bio Limited

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YD Bio announced that its affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified laboratory's authorized operating footprint to 46 U.S. states plus Washington D.C. and Guam. The expansion supports the company's DNA methylation-based early cancer detection operations and broadens patient access to blood-based testing services for various cancers.

YDES YDESW DNA methylation cancer detection clinical laboratory CLIA certification CAP accreditation laboratory expansion

Sentiment note

The company achieved significant regulatory expansion by obtaining licenses in two highly regulated states (Rhode Island and Pennsylvania), bringing its multi-state footprint to 46 states plus D.C. and Guam. This expansion directly supports the company's early cancer detection operations and broadens patient access, representing operational progress and growth in its diagnostic platform.

Neutral Apr 30, 2026 • 22:00 UTC GlobeNewswire Inc. • Yd Bio Limited

YD Bio Limited Reports Full Year 2025 Financial Results

YD Bio (Nasdaq: YDES) announced full-year 2025 financial results showing 17% net revenue increase to $596.8 million, driven by pharmaceutical sales growth and new product launches. However, the company reported a net loss of $8.3 million compared to $1.4 million in 2024, primarily due to a $3.2 million change in warrant liabilities and increased operating expenses from business expansion. The company ended 2025 with $6.0 million in cash and outlined 2026 strategic priorities including FDA submissions for its Limbal Stem Cell platform and pancreatic cancer detection program, along with planned M&A activities.

YDES YDESW DNA methylation cancer detection ophthalmologic innovations pharmaceutical sales Limbal Stem Cell platform pancreatic cancer early detection FDA regulatory pathway

Sentiment note

Mixed financial performance with positive revenue growth (17% increase) and successful business combination, but offset by significant net loss expansion ($8.3M vs $1.4M), declining gross margins due to product mix shift, and substantial warrant liability charges. While management commentary shows optimistic forward guidance with multiple clinical milestones planned for 2026, the deteriorating profitability and low cash position ($6.0M) present near-term operational concerns.

Positive Dec 16, 2025 • 14:00 UTC GlobeNewswire Inc. • Dr. Ethan Shen

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

YD Bio Limited plans to establish a new U.S. operations center in California to accelerate clinical development, regulatory engagement, and commercial access for cancer diagnostics and exosome-based therapeutics.

YDES YDESW biotechnology cancer detection DNA methylation operations expansion clinical development

Sentiment note

Company is expanding operations, investing in U.S. market, recruiting talent, and strategically positioning for clinical and commercial growth